Kiora Pharmaceuticals (KPRX) Price & Analysis

Compare

474 Followers

KPRX Stock Chart & Stats

Day’s Range― - ―

52-Week Range$2.25 - $4.29

Previous CloseN/A

Volume13.46K

Average Volume (3M)56.96K

Market Cap

$7.61M

Enterprise Value-$11.25M

Total Cash (Recent Filing)$24.11M

Total Debt (Recent Filing)$159.02K

Price to Earnings (P/E)4.7

Beta0.97

Next Earnings

Nov 17, 2025

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.54

Shares Outstanding3,043,857

10 Day Avg. Volume48,999

30 Day Avg. Volume56,964

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)0.00

Price to Sales (P/S)0.00

P/FCF Ratio0.00

Enterprise Value/Market Cap-1.48

Enterprise Value/Revenue-562.68

Enterprise Value/Gross Profit0.70

Enterprise Value/Ebitda1.14

Forecast

1Y Price Target

$11.00

Price Target Upside340.00% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering2

Bulls Say, Bears Say

Bulls Say

Intellectual PropertyThe U.S. patent for KIO-104 covers a wide range of ocular diseases, enhancing the company's intellectual property portfolio.

Market ExpansionKiora Pharmaceuticals announced a license deal, selling commercial rights for KIO-301 in Asia to Senju Pharmaceutical Co., receiving an immediate $1.25M option fee and potential deal value of $110M.

Bears Say

Clinical RisksRisks include failure of KIO-301 in clinical trials and failure to secure regulatory approval.

Financial PerformanceFor 4Q24, net loss was $4.2M, higher than the estimated loss of $2.7M.

Kiora Pharmaceuticals News

Kiora Pharmaceuticals granted new patent for KIO-104, says H.C. Wainwright

H.C. Wainwright reiterates a Buy rating and $10 price target on shares of Kiora Pharmaceuticals (KPRX) after the...

17d ago

KPRX

Positive Outlook for Kiora Pharmaceuticals: Buy Rating Affirmed Amid Promising Developments and Strategic Initiatives

Analyst Yi Chen from H.C. Wainwright reiterated a Buy rating on Kiora Pharmaceuticals and keeping the price target...

17d ago

KPRX

Kiora Pharmaceuticals Holds Annual Meeting, Elects Directors

Kiora Pharmaceuticals ( ($KPRX) ) has issued an announcement. On June 4, 2025, Kiora Pharmaceuticals held its Annual...

2M ago

KPRX

Kiora Pharmaceuticals: Strategic Partnerships and Promising Financial Prospects Drive Buy Rating

Maxim Group analyst Michael Okunewitch maintained a Buy rating on Kiora Pharmaceuticals (KPRX – Research Report) yesterday and...

2M ago

KPRX

Kiora Pharmaceuticals Secures Exclusive Option Agreement with Senju

An update from Kiora Pharmaceuticals ( ($KPRX) ) is now available. On May 30, 2025, Kiora Pharmaceuticals entered...

2M ago

KPRX

Kiora Pharmaceuticals Reports Q1 2025 Financial Results

Kiora Pharmaceuticals, Inc. ( ($KPRX) ) has released its Q1 earnings. Here is a breakdown of the information...

2M ago

KPRX

Kiora Pharmaceuticals: Strong Financial Position and Strategic Partnerships Propel Buy Rating

Kiora Pharmaceuticals (KPRX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday....

3M ago

KPRX

Kiora Pharmaceuticals’ KIO-104: Promising Preclinical Data and Strong Buy Rating

Maxim Group analyst Michael Okunewitch maintained a Buy rating on Kiora Pharmaceuticals (KPRX – Research Report) yesterday and...

3M ago

KPRX

Kiora Pharmaceuticals, Inc. (KPRX) Q1 Earnings Cheat Sheet

Kiora Pharmaceuticals, Inc. (KPRX) is scheduled to report 1st quarter earnings on 05/07/2025. Regarding Q1 estimates, Wall Street...

3M ago

KPRX

Kiora Pharmaceuticals: Promising Clinical Developments and Strong Financial Position Justify Buy Rating

Analyst Yi Chen of H.C. Wainwright reiterated a Buy rating on Kiora Pharmaceuticals (KPRX – Research Report), with...

4M ago

KPRX

Kiora Pharmaceuticals Advances Retinal Disease Pipeline

Kiora Pharmaceuticals, Inc. ( ($KPRX) ) has released its Q4 earnings. Here is a breakdown of the information...

5M ago

KPRX

Kiora Pharmaceuticals target ajusted to $54 from $6 at Ladenburg

Ladenburg raised the firm’s price target on Kiora Pharmaceuticals to $54 from $6 and keeps a Buy rating...

12M ago

KPRX

Kiora Pharmaceuticals Inc trading halted, news pending

19:50 EDT Kiora Pharmaceuticals Inc trading halted, news pending Published first on TheFly – the ultimate source for...

1y ago

KPRX

Kiora Pharmaceuticals files to sell 76.53M shares of common stock for holders

16:52 EST Kiora Pharmaceuticals files to sell 76.53M shares of common stock for holders Published first on TheFly...

1y ago

KPRX

KPRX FAQ

What was Kiora Pharmaceuticals, Inc.’s price range in the past 12 months?

Kiora Pharmaceuticals, Inc. lowest stock price was $2.25 and its highest was $4.29 in the past 12 months.

What is Kiora Pharmaceuticals, Inc.’s market cap?

Kiora Pharmaceuticals, Inc.’s market cap is $7.61M.

When is Kiora Pharmaceuticals, Inc.’s upcoming earnings report date?

Kiora Pharmaceuticals, Inc.’s upcoming earnings report date is Nov 17, 2025 which is in 101 days.

How were Kiora Pharmaceuticals, Inc.’s earnings last quarter?

Kiora Pharmaceuticals, Inc. released its earnings results on Aug 08, 2025. The company reported -$0.54 earnings per share for the quarter, beating the consensus estimate of -$0.605 by $0.065.

Is Kiora Pharmaceuticals, Inc. overvalued?

According to Wall Street analysts Kiora Pharmaceuticals, Inc.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Kiora Pharmaceuticals, Inc. pay dividends?

Kiora Pharmaceuticals, Inc. does not currently pay dividends.

What is Kiora Pharmaceuticals, Inc.’s EPS estimate?

Kiora Pharmaceuticals, Inc.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Kiora Pharmaceuticals, Inc. have?

Kiora Pharmaceuticals, Inc. has 3,043,857 shares outstanding.

What happened to Kiora Pharmaceuticals, Inc.’s price movement after its last earnings report?

Kiora Pharmaceuticals, Inc. reported an EPS of -$0.54 in its last earnings report, beating expectations of -$0.605. Following the earnings report the stock price went up 4.167%.

Which hedge fund is a major shareholder of Kiora Pharmaceuticals, Inc.?

Currently, no hedge funds are holding shares in KPRX

Company Description

Kiora Pharmaceuticals, Inc.

Kiora Pharmaceuticals (KPRX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies for treating ophthalmic disorders. The company operates primarily in the healthcare sector, with a commitment to addressing unmet medical needs in the field of ophthalmology. Kiora's core products are designed to treat a range of eye diseases and conditions, offering potential solutions for patients suffering from vision impairment and blindness.

Kiora Pharmaceuticals (KPRX) Earnings & Revenues

Historic Earnings Reports

KPRX Stock 12 Month Forecast

Average Price Target

$11.00

▲(340.00% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1":"$1","4":"$4","7":"$7","10":"$10","13":"$13"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":12,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$12.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":11,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$11.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":10,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$10.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1,4,7,10,13],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2024","6":"Dec<br/>2024","9":"Mar<br/>2025","12":"Jul<br/>2025","25":"Jul<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.82,3.526153846153846,4.2323076923076925,4.938461538461539,5.644615384615385,6.350769230769231,7.056923076923077,7.763076923076923,8.46923076923077,9.175384615384615,9.881538461538462,10.587692307692308,11.293846153846154,{"y":12,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.82,3.449230769230769,4.078461538461538,4.707692307692308,5.336923076923076,5.966153846153846,6.595384615384615,7.224615384615385,7.853846153846154,8.483076923076924,9.112307692307693,9.741538461538461,10.37076923076923,{"y":11,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.82,3.3723076923076922,3.924615384615384,4.476923076923077,5.029230769230769,5.581538461538461,6.133846153846154,6.686153846153846,7.238461538461538,7.7907692307692304,8.343076923076923,8.895384615384614,9.447692307692307,{"y":10,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":5.89,"date":1709251200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.9,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.35,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.53,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.57,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.6,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.44,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.3,"date":1735689600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":4.03,"date":1738368000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":3.25,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.28,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.85,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.82,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >